Kintara Therapeutics, Inc. (NASDAQ:KTRA) CFO Purchases $19,516.00 in Stock
Kintara Therapeutics, Inc. (NASDAQ:KTRA) CFO Anthony Scott Praill acquired 28,700 shares of the company's stock in a transaction that occurred on Wednesday, December 8th. The shares were bought at an average…
From the Equity Insider archive. This article dates from Dec 10, 2021 and is preserved as first published.
Kintara Therapeutics, Inc. (NASDAQ:KTRA) CFO Anthony Scott Praill acquired 28,700 shares of the company’s stock in a transaction that occurred on Wednesday, December 8th. The shares were bought at an average cost of $0.68 per share, for a total transaction of $19,516.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Kintara Therapeutics stock traded down $0.03 during midday trading on Thursday, reaching $0.68. The company’s stock had a trading volume of 398,935 shares, compared to its average volume of 1,264,051. The stock’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $1.34. Kintara Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.35. The stock has a market capitalization of $33.00 million, a P/E ratio of -0.84 and a beta of 1.67.
Kintara Therapeutics (NASDAQ:KTRA) last announced its quarterly earnings data on Monday, November 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). Equities research analysts predict that Kintara Therapeutics, Inc. will post -0.71 earnings per share for the current year.
Kintara Therapeutics (NASDAQ:KTRA) last announced its quarterly earnings data on Monday, November 15th.
KTRA has been the subject of a number of research analyst reports. Maxim Group initiated coverage on Kintara Therapeutics in a research note on Friday, October 8th. They issued a “buy” rating and a $3.00 price target for the company. HC Wainwright initiated coverage on Kintara Therapeutics in a research note on Tuesday, September 28th. They issued a “buy” rating and a $6.00 price target for the company. Finally, Aegis decreased their price target on Kintara Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, September 30th.
Large investors have recently made changes to their positions in the company. Two Sigma Investments LP purchased a new position in shares of Kintara Therapeutics in the third quarter worth about $47,000. Virtu Financial LLC raised its stake in shares of Kintara Therapeutics by 30.9% in the second quarter. Virtu Financial LLC now owns 54,728 shares of the company’s stock worth $124,000 after purchasing an additional 12,916 shares during the last quarter. Golden State Equity Partners purchased a new position in shares of Kintara Therapeutics in the second quarter worth about $162,000. Citadel Advisors LLC purchased a new position in shares of Kintara Therapeutics in the first quarter worth about $134,000. Finally, State Street Corp raised its stake in shares of Kintara Therapeutics by 688.1% in the second quarter. State Street Corp now owns 107,974 shares of the company’s stock worth $245,000 after purchasing an additional 94,274 shares during the last quarter. Hedge funds and other institutional investors own 8.36% of the company’s stock.
Kintara Therapeutics Company Profile
Kintara Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. It focuses on VAL-083 and REM-001 pipelines. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
